A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Partner of Industry and Medical Professionals for Market Data, Independent Perspective, & Objective Analysis
Latest Reports Latest NewsMarket Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Physician Surveys
For 20+ years, we have surveyed physicians to provide both physicians & industry professionals unbiased insight into the market.
Complete a Survey
On average, our surveys take only 5 to 15 minutes to complete. Survey results help you analyze practice patterns, evaluate treatment choices, and benchmark your practice.
Benchmark Your Performance
Benchmark reports allow you to gauge your performance, track your practice metrics over time, and compare your practice to national averages.
View Market Insights & Analytics
Additional free data tools include instant survey results, weekly polls, PowerPoint charts, and more.
Learn More Register TodayLatest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 393
Comprehensive Pages
- 43
Company Profiles
- 11
IOL Categories Forecasted
- 229
Tables & Figures
Latest Industry News & Trends
2/26/2021
BreakingPharmaRefractiveRegulation
Allergan Submits New Drug Application to US FDA for Presbyopia Drop
Allergan, an AbbVie company, announced Feb. 25 that it had submitted a new drug application (NDA) to the US FDA for AGN-190584 (pilocarpine 1.25%) ophthalmic solution for symptoms of presbyopia. Th...
2/26/2021
BreakingCataractIOLRegulation
AcuFocus Submits US Premarket Approval Application for IC-8 Small Aperture IOL
AcuFocus announced Feb. 23 that it had submitted a premarket approval (PMA) application to the US FDA for its IC-8 small aperture IOL. The IC-8 is an aspheric monofocal lens that features an embedd...
2/26/2021
BreakingCataractDry EyeEarningsRefractiveSurgical
2020 Earnings Roundup: Alcon, Bausch, Horizon, and Four More
Alcon reported Feb. 23 that full-year 2020 revenue totaled $6.8 billion, a decrease of 8 percent on a reported and constant currency basis, from $7.4 billion in 2019. The company said a substantial...
2/26/2021
BreakingGene TherapyRetina
Oculogenex Gene Therapy Startup Wins Winning Pitch Challenge—Retina
Ophthalmologist Hema Ramkumar, MD, won the 2021 Winning Pitch Challenge—Retina, a virtual competition held Feb. 6. Ramkumar, a surgeon at Retina Consultants of Orange County, is the founder of Ocul...
2/26/2021
BreakingInstrumentsSurgical
Oertli Begins Construction of New Production and Logistics Factory
Swiss ophthalmic surgical instrument maker Oertli announced Feb. 17 that it had started construction on a new factory at its location in Berneck. The three-story production and logistics building w...
2/26/2021
BreakingDry EyeSurgical
I-MED Pharma Shifts Surgical Portfolio to Keir to Focus on Dry Eye
I-MED Pharma, of Montreal, Canada, announced Feb. 2 that Keir Surgical had taken ownership of its ophthalmic surgical portfolio. No financial details were given. I-MED said it would reinvest the pr...
2/26/2021
BreakingDealsGlaucomaPharma
UK’s Medicom Buys Generic Bimatoprost from Famar of Spain
Medicom Healthcare Limited, of the UK, announced Feb. 10 that it had acquired the product dossier of bimatoprost 0.3 mg/mL, 3ml, preservative-free eye drop solution from Spain’s Famar Health Care S...
2/26/2021
BreakingGene TherapyRetina
Ocugen Gene Therapy Candidate for RP, LCA Gains Orphan Status in EU
Ocugen announced Feb. 23that the European Commission had granted orphan medicinal product designation for its OCU400 gene therapy candidate for retinitis pigmentosa (RP) and Leber congenital amauro...
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.